Lilly is building an oncology franchise with the same speed and conviction it used to dominate GLP-1s. The Kelonia Therapeutics deal—up to $7 billion ($3.25 billion upfront plus milestones) for a clinical-stage in vivo CAR-T platform in multiple myeloma—is the third major acquisition Lilly has announced in 2026. That brings the company’s total announced deal value this year to approximately $17.2 billion across Orna Therapeutics ($2.4 billion, in vivo CAR-T for autoimmune, February), Centessa Pharmaceuticals ($7.8 billion, narcolepsy, March), and now Kelonia. Lilly EVP Jacob Van Naarden said these deals are “all part of Lilly’s plan to grow beyond the GLP-1 drugs for obesity and diabetes that Lilly is best known for.” The Kelonia story is particularly striking: a company that nearly ran out of cash three times, raised only $60 million over five years, and just landed a $7 billion exit. Meanwhile, today is the biggest day at AACR 2026. Revolution Medicines presents combination daraxonrasib data in first-line pancreatic cancer and zoldonrasib Phase 1 data in NSCLC—two presentations that will define the next phase of the RAS oncology conversation. And obesity deal commitments hit $22 billion in Q1 2026, already exceeding the full-year 2025 total.
Top Story: Lilly Acquires Kelonia Therapeutics for Up to $7B to Lead the In Vivo CAR-T Race
What Happened: Eli Lilly announced a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage Boston-based biotech developing in vivo CAR-T cell therapies. Kelonia shareholders will receive up to $7 billion in cash: $3.25 billion upfront and subsequent payments upon achievement of clinical, regulatory, and commercial milestones. Close is expected in H2 2026. The Wall Street Journal first reported the deal was imminent on Sunday evening.
The Technology: Why In Vivo CAR-T Is the Next Frontier
To understand why Lilly is paying $3.25 billion upfront for a Phase 1 company, you need to understand the fundamental limitation of current CAR-T therapy. Today’s approved CAR-T treatments—Yescarta, Abecma, Carvykti—are all ex vivo therapies. They require removing a patient’s T-cells through leukapheresis, shipping those cells to a manufacturing facility, genetically engineering them over two to four weeks to recognize and attack cancer cells, and then reinfusing the modified cells back into the patient. Before reinfusion, patients undergo lymphodepletion chemotherapy to suppress their existing immune system so the engineered cells can engraft.
The process works. Ex vivo CAR-T has produced durable remissions in blood cancers that were previously untreatable. But the logistics are a barrier to scale. The treatment requires specialized manufacturing infrastructure. Wait times can extend beyond a month. And the entire process limits CAR-T access to a fraction of the patients who could benefit.
Kelonia’s proprietary in vivo gene placement system (iGPS) takes a fundamentally different approach. The technology uses engineered lentiviral-based particles designed to selectively enter T-cells inside a patient’s body and reprogram them to attack cancer. A single intravenous infusion delivers the therapy. No cell harvesting. No manufacturing wait time. No lymphodepletion chemotherapy. No reinfusion.
If in vivo CAR-T works at scale, it could transform cell therapy from a complex, logistically constrained procedure into something closer to a standard infusion—dramatically expanding the patient population that can access the treatment.
The Lead Asset: KLN-1010
KLN-1010 is a potentially first-in-class lentiviral in vivo anti-BCMA CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma. Early clinical data were presented in a plenary session at ASH 2025. Lilly EVP Jacob Van Naarden called the early data “highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia’s platform.”
The “platform” designation is critical. The iGPS technology is not specific to myeloma—it is a delivery system that could potentially be directed at any target by changing the CAR construct. This gives Lilly optionality beyond the lead indication, which is why the deal is structured with milestone payments tied to clinical, regulatory, and commercial achievements across what will likely be a multi-indication development program.
The Founding Story: From $60M to $7B
STAT reported that Kelonia nearly ran out of cash three times during its five-year history and had raised only $60 million total before Lilly’s offer. Venrock, which incubated the company (originally called Elcano Therapeutics), shared its original investment memo and pitch deck publicly following the deal announcement.
The trajectory from $60 million in total funding to a $7 billion exit is extraordinary by any standard. It illustrates a principle that repeats across biotech: companies with transformative platform technology but limited commercial appeal to traditional VC investors can generate outsized returns when the right strategic acquirer identifies the platform’s full potential. Lilly saw in Kelonia not just a myeloma drug, but a delivery platform that could underpin an entire in vivo cell therapy franchise spanning oncology and autoimmune disease.
Lilly’s 2026 Deal Spree: $17.2B in Three Months
The Kelonia acquisition must be understood in the context of Lilly’s broader M&A campaign this year:
Orna Therapeutics (February): $2.4 billion for in vivo CAR-T technology based on circular RNA, targeting autoimmune diseases. This gives Lilly an in vivo cell therapy platform in a non-oncology therapeutic area.
Centessa Pharmaceuticals (March): $7.8 billion ($38 per share plus $9 CVR) for an OX2R agonist pipeline targeting narcolepsy and sleep-wake disorders. Lilly’s most significant push into neuroscience.
Kelonia Therapeutics (April): Up to $7 billion ($3.25 billion upfront) for lentiviral in vivo CAR-T in multiple myeloma. Complements Orna by providing a second in vivo delivery platform with a different technology (lentiviral versus circular RNA) and a different therapeutic focus (oncology versus autoimmune).
Total: approximately $17.2 billion in announced deal value. Lilly now owns two distinct in vivo CAR-T platforms spanning both cancer and autoimmune indications—a franchise-level bet that in vivo will eventually replace ex vivo as the standard approach to cell therapy.
The Competitive Context: Lilly vs. Gilead and BMS
The in vivo CAR-T bet positions Lilly against Gilead and BMS, which currently dominate the ex vivo CAR-T market. Gilead’s Yescarta and the recently acquired Arcellx (anito-cel, FDA decision expected H2 2026) anchor its cell therapy franchise. BMS’s Abecma and Breyanzi are established commercial products. Both companies are invested in the current-generation technology.
Lilly is making a different wager: that the current ex vivo approach will eventually be superseded by in vivo delivery, and that owning the leading in vivo platforms now—before any in vivo CAR-T has been approved—gives Lilly a first-mover advantage in a market transition that could take five to ten years to play out. The risk is proportional to the ambition: no in vivo CAR-T therapy has been approved, and the field faces unresolved questions about durability, targeting specificity, and manufacturing consistency at commercial scale.
Our Pro brief analyzes why Lilly’s dual-platform in vivo CAR-T thesis (Kelonia lentiviral plus Orna circular RNA) could eventually replace ex vivo cell therapy, how the $60M-to-$7B Kelonia founding story reflects biotech’s valuation dynamics, and what the $17.2B in 2026 M&A says about Lilly’s strategic diversification beyond GLP-1. [Details below.]
What to Watch
The Kelonia deal is expected to close in H2 2026. KLN-1010 Phase 1 data updates will be the clinical catalysts that determine whether the in vivo approach delivers on its theoretical promise. Watch for expansion cohort data at hematology conferences later this year. The integration of Kelonia and Orna into a unified in vivo cell therapy franchise will be the strategic challenge—two different delivery platforms (lentiviral versus circular RNA), two different therapeutic areas (oncology versus autoimmune), and a Boston-area geographic concentration that Lilly will need to manage alongside its Indianapolis core.
AACR Day 5: Revolution Medicines Presents Today
Today is the most anticipated day of AACR 2026. Revolution Medicines has two key presentations that will define the next phase of the RAS oncology conversation:
Mini-Symposium: Phase 1/2 data on daraxonrasib plus chemotherapy in first-line metastatic PDAC. This is the first look at combination data in untreated pancreatic cancer patients.
Plenary Session: Phase 1 data on zoldonrasib (RAS G12D-selective) in previously treated KRAS G12D mutant non-small cell lung cancer. This extends the RAS(ON) platform beyond pancreatic cancer into the largest solid tumor indication.
Both presentations build on the Phase 3 RASolute 302 monotherapy data—13.2 months median OS versus 6.7 months, HR 0.40, p<0.0001—that sent RVMD up 41% two weeks ago and prompted the $2 billion upsized offering.
Why Today’s Data Matters: The combination presentation in first-line PDAC will show whether adding daraxonrasib to standard chemotherapy in untreated patients produces additive benefit. If the data shows meaningful improvement, it validates the design of the RASolute 303 Phase 3 trial (now enrolling) and opens the first-line market—roughly double the second-line patient population. The zoldonrasib NSCLC data will determine whether Revolution’s G12D-selective inhibitor has meaningful single-agent activity in lung cancer, validating the platform’s breadth beyond pancreatic cancer.
We will cover both data sets in detail in tomorrow’s email.
Clinical Updates
AstraZeneca’s Tozorakimab Hits in Third COPD Phase 3 Trial
AstraZeneca’s tozorakimab, an anti-IL-33 antibody, met its primary endpoint in the third of three Phase 3 trials in COPD. This sets up global regulatory filings. Tozorakimab targets the IL-33 pathway, the same target as Sanofi’s itepekimab (partnered with Regeneron), though through a different mechanism. The COPD biologic market is expected to be one of the largest new therapeutic categories in respiratory medicine, with multiple companies pursuing biologics in a patient population that currently has no approved biologic therapy.
The competitive landscape in COPD biologics is forming rapidly. Sanofi has lunsekimig (TSLP/IL-13) and itepekimab (IL-33) in Phase 3 COPD studies. AstraZeneca now has tozorakimab (IL-33) across three positive Phase 3 trials. The question is which mechanism or combination of mechanisms will produce the most clinically meaningful benefit in a heterogeneous disease.
Obesity and Diabetes Deal Commitments Hit $22B in Q1
A J.P. Morgan report cited by BioSpace found that obesity and diabetes deal commitments reached $22 billion in Q1 2026, already exceeding the full-year 2025 total of $20.3 billion. The figure captures M&A, licensing, and partnership commitments across the metabolic space.
Why This Matters: The acceleration in capital flowing into obesity is consistent with every other signal in the market: Kailera’s $625 million IPO, Lilly’s Foundayo launch, Novo’s subscription pricing model, and the continued expansion of the GLP-1 treatable population. The J.P. Morgan data quantifies what the deal flow and capital raises have been signaling qualitatively—the obesity market is absorbing capital at a pace that exceeds any other therapeutic area in biopharma.
Strategic Themes
1. Lilly Is Building a Next-Generation Cell Therapy Franchise While Competitors Own the Current One
Gilead and BMS dominate ex vivo CAR-T today. Lilly is betting that in vivo CAR-T will dominate tomorrow. The Kelonia and Orna acquisitions give Lilly two distinct delivery platforms (lentiviral and circular RNA) across two therapeutic areas (oncology and autoimmune). This is not a hedging strategy—it is a platform bet on a technological transition that has not yet occurred. If in vivo CAR-T delivers on its promise, Lilly will own the leading positions in the next generation of cell therapy. If the technology faces unexpected barriers to durability or specificity, Lilly will have spent billions on platforms that remain early-stage for years longer than expected.
2. $17.2B in Three Months Signals That Lilly’s Diversification Is Systematic, Not Opportunistic
Three acquisitions across three different therapeutic areas (autoimmune cell therapy, narcolepsy, oncology cell therapy) in under three months is not a company reacting to opportunities as they arise. It is a company executing a pre-planned diversification strategy designed to reduce GLP-1 concentration risk. Each deal addresses a different strategic objective: Orna diversifies the modality platform into autoimmune, Centessa diversifies the therapeutic footprint into neuroscience, and Kelonia diversifies the oncology pipeline into next-generation cell therapy. The pattern is deliberate.
3. The $60M-to-$7B Kelonia Story Is the Template for Platform Biotech Value Creation
Kelonia raised $60 million total, nearly went bankrupt three times, and just exited for $7 billion. The lesson for founders and investors is that platform technologies with transformative potential can generate extraordinary returns even when the capital journey is nonlinear. The key variable was not capital efficiency or commercial revenue—it was the platform’s strategic value to the right acquirer at the right moment. Lilly needed in vivo CAR-T. Kelonia had the leading lentiviral platform. The match produced a valuation that no amount of VC fundraising or IPO proceeds could have achieved.
4. AACR Today Will Determine Whether Revolution Is a Single-Indication Company or a Platform
The combination data in first-line PDAC and the zoldonrasib data in NSCLC are the two presentations that will define whether Revolution Medicines becomes a multi-indication oncology platform or remains concentrated in second-line pancreatic cancer. The Phase 3 monotherapy data was transformative for one indication. Today’s presentations will determine whether the RAS(ON) platform extends to first-line treatment and to lung cancer—a determination that could double or triple the franchise’s commercial potential.
Frequently Asked Questions
What is Kelonia Therapeutics, and why is Lilly paying up to $7B?
Kelonia is a clinical-stage Boston-based biotech developing in vivo CAR-T cell therapies using its proprietary in vivo gene placement system (iGPS). Unlike current ex vivo CAR-T therapies, which require cell harvesting, manufacturing, and lymphodepletion chemotherapy, Kelonia’s approach involves a single intravenous infusion that reprograms T-cells inside the patient’s body. The lead asset KLN-1010 is in Phase 1 for relapsed/refractory multiple myeloma with early data presented at ASH 2025.
What is the difference between in vivo and ex vivo CAR-T?
Ex vivo CAR-T (Yescarta, Abecma, Carvykti) requires removing a patient’s T-cells, engineering them in a lab over two to four weeks, and reinfusing them after lymphodepletion chemotherapy. In vivo CAR-T delivers engineered viral particles through a single infusion that enter and reprogram T-cells inside the body—no cell harvesting, no manufacturing wait time, no lymphodepletion. If the approach works at scale, it could dramatically expand access and reduce costs.
How does the Kelonia deal fit with Lilly’s Orna acquisition?
Together they give Lilly two distinct in vivo CAR-T platforms: Kelonia uses lentiviral delivery for oncology (myeloma), and Orna uses circular RNA for autoimmune diseases. Two different delivery systems, two different therapeutic areas, but the same strategic thesis—that in vivo cell therapy will eventually replace the current ex vivo approach.
How much has Lilly spent on M&A in 2026?
Approximately $17.2 billion in announced deal value across three acquisitions: Orna Therapeutics ($2.4 billion), Centessa Pharmaceuticals ($7.8 billion), and Kelonia Therapeutics (up to $7 billion). Each targets a different therapeutic area—autoimmune, narcolepsy, and oncology—reflecting a systematic diversification strategy beyond GLP-1 dependence.
How did Kelonia go from $60M raised to a $7B exit?
Kelonia, originally called Elcano Therapeutics, was incubated by Venrock and raised only $60 million over five years. STAT reported the company nearly ran out of cash three times. The transformative exit reflects the strategic value of the iGPS platform to the right acquirer: Lilly needed in vivo CAR-T technology, and Kelonia had the leading lentiviral approach with early clinical data from a plenary presentation at ASH 2025.
What is Revolution Medicines presenting at AACR today?
Two key presentations: earlier-phase data on daraxonrasib plus chemotherapy in first-line metastatic PDAC (mini-symposium) and Phase 1 data on zoldonrasib in KRAS G12D mutant NSCLC (plenary session). The first-line combination data will signal whether daraxonrasib’s benefit extends to untreated patients. The zoldonrasib data will determine whether the RAS(ON) platform extends beyond pancreatic cancer into lung cancer.
What did the J.P. Morgan obesity deal report show?
Obesity and diabetes deal commitments reached $22 billion in Q1 2026, already exceeding the full-year 2025 total of $20.3 billion. The figure captures M&A, licensing, and partnership commitments across the metabolic space and quantifies the acceleration in capital flowing into obesity drug development.
What is AstraZeneca’s tozorakimab?
An anti-IL-33 antibody that met its primary endpoint in the third of three Phase 3 trials in COPD, setting up global regulatory filings. Tozorakimab targets the same pathway (IL-33) as Sanofi’s itepekimab but represents a separate development program. The COPD biologic market is expected to be one of the largest new therapeutic categories in respiratory medicine.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly’s In Vivo CAR-T Thesis. We analyze why owning two in vivo platforms (Kelonia lentiviral plus Orna circular RNA) across oncology and autoimmune represents a franchise-level bet on a technology transition, how it positions against Gilead and BMS in the current ex vivo market, and the unresolved scientific questions around durability, specificity, and commercial-scale manufacturing.
Kelonia’s $60M-to-$7B Founding Story. We examine what the capital-constrained journey from Venrock incubation to a $7 billion exit reveals about biotech valuation dynamics, platform versus product investing, and how strategic acquirer demand can create exits that traditional VC math cannot model.
AACR Day 5: What the Data Needs to Show. We preview what the daraxonrasib combination data and zoldonrasib NSCLC data need to demonstrate to justify Revolution’s current market cap, and frame the presentations against the RASolute 302 Phase 3 benchmark.
Plus: Lilly $17.2B M&A integration risk assessment, AstraZeneca tozorakimab COPD competitive landscape, Q1 obesity deal commitments analysis, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
